A metaanalysis of controlled trials of neuroleptic treatment in dementia

LS Schneider, VE Pollock… - Journal of the American …, 1990 - Wiley Online Library
Prior qualitative literature reviews about the use of neuroleptics in dementia suggest that
they are “modestly effective” in treating agitation and that no single neuroleptic is better than …

Efficacy and safety of neuroleptics in behavioral disorders associated with dementia

KL Lanctôt, TS Best, N Mittmann, BA Liu… - The Journal of clinical …, 1998 - psychiatrist.com
Background: Neuroleptics are commonly used to treat behavioral disordersassociated with
dementia. However, their safety and efficacy have not been wellestablished in these …

Neuroleptics and Alternative Treatments: Management of Behavioral Symptoms and Psychosis on Alzheimer's Disease and Related Conditions

RE Wragg, DV Jeste - Psychiatric Clinics of North America, 1988 - Elsevier
A majority of demented patients experience agitation, psychotic symptoms, or other specific
behavioral problems at some time in the course of illness. Neuroleptics are the most widely …

Neuroleptics in the treatment of dementia

T Sunderland, MA Silver - International Journal of Geriatric …, 1988 - Wiley Online Library
The authors review the history of neuroleptic treatment in dementia. The initial review of 34
studies published since 1954 was limited to the 20 double‐blind and/or placebo‐controlled …

Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment—controlled pilot study

S Bridges-Parlet, D Knopman… - Journal of Geriatric …, 1997 - journals.sagepub.com
Among dementia patients in long-term care facilities, neuroleptics (NL) are frequently
prescribed for the treatment of agitation. Although good clinical practice and federal law …

Neuroleptic drugs in dementia: benefits and harm

C Ballard, R Howard - Nature Reviews Neuroscience, 2006 - nature.com
Neuroleptic (antipsychotic) drugs are often used to treat psychiatric symptoms frequently
seen in dementia, but their use is controversial. We present a new meta-analysis to assess …

A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor …

CG Ballard, A Thomas, J Fossey, L Lee… - Journal of Clinical …, 2004 - psychiatrist.com
Background: Although few placebo-controlled neuroleptic discontinuation studies have
been conducted in people with dementia, such studies are essential to inform key clinical …

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

KM Sink, KF Holden, K Yaffe - Jama, 2005 - jamanetwork.com
ContextNeuropsychiatric symptoms of dementia are common and associated with poor
outcomes for patients and caregivers. Although nonpharmacological interventions should be …

Pharmacologic treatment of agitation associated with dementia

SC Risse, R Barnes - Journal of the American Geriatrics …, 1986 - Wiley Online Library
Pharmacotherapy of aggressive or agitated behaviors in the dementia patient has not been
studied extensively, despite the prevalence of this problem. Neuroleptics have the most …

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

C Ballard, MM Lana, M Theodoulou, S Douglas… - PLoS …, 2008 - journals.plos.org
Background There have been increasing concerns regarding the safety and efficacy of
neuroleptics in people with dementia, but there are very few long-term trials to inform clinical …